Clinical trials
Observational Crohn Disease trials in Germany
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
37 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2007 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 3 |
| 2012 | 1 |
| 2014 | 2 |
| 2015 | 3 |
| 2017 | 2 |
| 2018 | 2 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 2 |
| 2023 | 2 |
| 2024 | 6 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Unknown status | 10 |
| Recruiting | 5 |
| Active, not recruiting | 4 |
| Withdrawn | 2 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Erlangen-Nürnberg Medical School | 8 |
| AbbVie | 3 |
| Ced Service GmbH | 2 |
| Ferring Pharmaceuticals | 2 |
| Takeda | 2 |
| Universität Duisburg-Essen | 2 |
| Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 1 |
| Biogen | 1 |
| Centocor, Inc. | 1 |
| Charite University, Berlin, Germany | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Crohn Disease | 37 |
| Colitis, Ulcerative | 21 |
| Inflammatory Bowel Diseases | 11 |
| Arthritis, Rheumatoid | 2 |
| Gastrointestinal Diseases | 2 |
| Irritable Bowel Syndrome | 2 |
| Rheumatic Diseases | 2 |
| Arthritis, Psoriatic | 1 |
| Asthma | 1 |
| Axial Spondyloarthritis | 1 |
Trials
Showing 1 to 25 of 37. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.